

Overview

Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma

Program Director: Robert Orlowski, MD, PhD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

February 25, 2017 – Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, TX 77030; Phone: 713-796-0080

Jointly Provided by

The A. Webb Roberts Center for CME of Baylor Scott & White Health, CancerNet and American Health Resource, Inc

Educational Grants

Amgen, Inc.

For online registration and more information visit: www.cancernetus.com

Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in multiple myeloma. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Statement of Need/Program Overview

This symposium is intended to improve care of patients with multiple myeloma by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Learning Objectives

- Describe the multiple myeloma (MM) disease definitions and diagnostic criteria based on IMWG guidelines
- Outline the classification and risk stratification on MM and smoldering MM
- Identify and select ASCT and/or AST in transplantation eligible patients with newly diagnosed MM
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active MM
- Customize the use of maintenance therapy approaches in the post-transplant and non-transplant settings based on patient- and disease related factors including cytogenetic profile
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Describe the natural history of precursor disorder, either smoldering myeloma or MGUS and see whether disease state can be altered by treating earlier to avoid progression to MM
- Assess the ongoing clinical trials investigating the innovative approaches for MM and refer patients for study participation.

Faculty

Elisabet E. Manasanch, MD, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Gareth Morgan, MD, PhD, Professor of Medicine, Director of the Myeloma Institute, University of Arkansas for Medical Sciences, Arkansas, AR

Robert Orlowski, MD, PhD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Jatin J. Shah, MD, Associate Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael Wang, MD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Registration Fee

Registration fee partially covers continental breakfast, lunch and syllabus book

	Early Registration Fee (Up to 1/31/17)	Discounted Registration Fee (2/1/17 to 2/15/17)	Regular Registration Fee (2/16/17 to 2/25/17)
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Registered Nurses	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Nurse Practitioners	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> *Industry	\$350.00	\$400.00	\$450.00

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Check
Credit Card Number _____ Expiration Date _____
Name and address† _____ Email _____
Pharmacist e-profile NABP# _____ Pharmacist DOB (MMDD) _____

Signature _____

†as given on the monthly credit card statement

No refund. Substitution is allowed.

Register online at www.cancernetus.com

Please make checks payable to **CancerNet**. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. For questions if any please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

Physician Continuing Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 5.25 contact hours. Please check with licensing board to verify credits can be claimed in your state.

Pharmacist Continuing Education

Accreditation Statement



American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This activity provides 5.25 contact hours (0.525 CEUs) - Knowledge based credits
ACPE Universal Activity Number: 0280-9999-16-073-L01-P

Participant Requirements for Credit (Nurses and Pharmacists):

- Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
- Participants can earn Continuing Education credits for this program by electronically logging onto the website <https://ce.ahrevents.com/> and completing the session evaluation form for sessions attended.
 - **Nurses:** After completion of the evaluation, certificate of credit can be printed.
 - **Pharmacists:** After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.
 - ***Only Certificates of Credit issued from CPE Monitor are valid in the US**
 - * **CPE Monitor will not accept credits after 60 days from the session date**
- All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation: All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

Agenda

Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma Houston, TX – February 25, 2017		
7:00 AM	Registration and Breakfast	
8:25 AM	Introduction and Opening Remarks	Robert Orłowski, MD, PhD
8:30 AM	State of the Art in Biology, Therapy and Patient Care of Multiple Myeloma (MM): A 2016 Update	Robert Orłowski, MD, PhD
9:00 AM	Update on MM Disease Definitions and Diagnostic Criteria Based on IMWG Guidelines	Gareth Morgan, MD
9:30 AM	Update on Classification and Risk Stratification on MM and Smoldering MM	TBD
10:00 AM	Panel Discussion and Case Presentation	Robert Orłowski, MD, PhD/Gareth Morgan, MD/ TBD
10:15 AM	BREAK	
10:30 AM	Update on ASCT and AST in Transplantation-Eligible Patients With Newly Diagnosed MM	Jatin Shah, MD
11:00 AM	An Overview on Systemic Therapy for Patients with Newly Diagnosed Active MM	Elizabeth Manasanch, MD
11:30 PM	Outline the Selection, Sequencing and/or Combination of Novel Therapies for Patients with Relapsed/refractory MM	Gareth Morgan, MD
12:00 PM	Panel Discussion and Case Presentation	Jatin Shah, MD/Elizabeth Manasanch, MD/Gareth Morgan, MD
12:15 PM	LUNCH	
1:15 PM	Describe the Smoldering Myeloma or MGUS and Whether Disease State can be Altered by Treating Earlier to Avoid Progression to MM	TBD
1:45 PM	Maintenance Therapy Approaches in the Post-transplant and Non-transplant Settings Based on Patient- and Disease Related Factors Including Cytogenetic Profile	Michael Wang, MD
2:15 PM	BREAK	
2:30 PM	New Drugs and Clinical Trials Investigating the Innovative Approaches for MM: Refer Patients for Study Participation	Robert Orłowski, MD, PhD
3:00 PM	Panel Discussion and Case Presentation	TBD/Michael Wang, MD/ Robert Orłowski, MD, PhD
3:15 PM	Closing Remarks and Adourn	Robert Orłowski, MD, PhD